Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose combination of two small molecule drugs, neostigmine methylsulfate and raceanisodamine hydrochloride. Neostigmine methylsulfate is a reversible cholinesterase inhibitor that increases acetylcholine levels at neuromuscular junctions by inhibiting acetylcholinesterase, thereby enhancing both nicotinic and muscarinic receptor stimulation. It is primarily used to reverse non-depolarizing neuromuscular blockade after surgery, treat myasthenia gravis, paralytic ileus, and postoperative urinary retention[2][5][6]. Raceanisodamine hydrochloride (also known as anisodamine) is a naturally occurring atropine derivative with anticholinergic properties; it acts as a muscarinic acetylcholine receptor antagonist and has been used in China for its antispasmodic effects on smooth muscle and to counteract cholinergic side effects[7]. The combination may be intended to balance the pro-cholinergic effects of neostigmine with the antimuscarinic actions of raceanisodamine, reducing adverse muscarinic side effects such as bradycardia or excessive secretions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neostigmine methylsulfate + raceanisodamine hydrochloride.